Data Synthesis: No trials evaluated screening or monitoring, and 110 evaluated treatments. Angiotensin-converting enzyme inhibitors (relative risk, 0.65 [95% CI, 0.49 to 0.88]) and angiotensin II–receptor blockers (relative risk, 0.77 [CI, 0.66 to 0.90]) reduced end-stage renal disease versus placebo, primarily in patients with diabetes who have macroalbuminuria. Angiotensin-converting enzyme i...

Angiotensin-converting enzyme (ACE) plays an important role in regulating blood pressure the body by converting angiotensin-I into angiotensin-II. It is basic component of Renin angiotensin aldosterone system (RAAS), imbalance RAAS may leads to many cardiovascular and renal diseases. There are marketed available drugs for inhibition ACE, but prolonged use some cause progressive side effects. Re...

Since the introduction of the first angiotensin-converting enzyme inhibitor (ACEI), captopril, in 1981, ACEIs have become a mainstay of antihypertensive therapy. In addition to lowering blood pressure, there is overwhelming evidence that ACEIs (and angiotensin receptor blockers) provide end-organ protection independent of their blood pressure–lowering properties in diseases such as congestive h...

Angiotensin converting enzyme (ACE) inhibitors are excellent antihypertensive agents and are becoming widely used as first-line therapy for chronic hypertension in women of reproductive age owing to their efficacy and few side effects. Reports of adverse fetal and neonatal effects from the use of ACE inhibitors in pregnancy in both animal and human studies prompted recommendations against their...

AIM To evaluate the efficacy of angiotensin converting enzyme inhibitors Enalapril, Fosonopril and Moexipril on mean and systolic pulmonary artery pressure. MATERIAL AND METHODS The study included Ill patients with chronic obstructive bronchopneumopathies associated with arterial hypertension and mild to moderate heart failure (NYHA I-II class). The patients were examined at baseline and afte...

BACKGROUND Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) taking angiotensin-converting enzyme (ACE) inhibitors. Elevated aldosterone levels may reflect incomplete inhibition of the vascular converting enzyme during long-term ACE inhibition. We simultaneously measured plasma aldosterone levels and the degree of inhibition of the vascular converting enzyme in...

1. The crucial role played by the renin-angiotensin-aldosterone system in the cardiovascular system and the immense therapeutic potential of angiotensin-converting enzyme inhibitors and, more recently, angiotensin II receptor blocking agents, in both heart failure and post-myocardial infarction is becoming increasingly evident. Polymorphisms within the genes controlling this enzyme system are c...